Abstract: Some embodiments of the present disclosure provide a laminating equipment for a Radio Frequency Identification (RFID) tire tag. The laminating equipment includes: a frame, a feeding mechanism, wherein the feeding mechanism is provided on the frame, and a laminating mechanism, wherein the laminating mechanism is provided on the frame. The laminating mechanism is configured to press rubber and an electronic chip of materials to be fed from the feeding mechanism. The feeding mechanism includes a support frame, a coiling portion which is provided on the support frame, and a driving wheel which is rotationally provided on the support frame. One end of the material to be fed is provided on the coiling portion, and the other end cooperates with the driving wheel, so as to move the material to be fed under a driving of the driving wheel. The technical solution of the present disclosure may solve a problem in the conventional art that the efficiency of manual feeding is low.

Abstract: This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b?/? TICs). The Cbl-b?/? TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.

Abstract: A biaryl compound. Specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a combination of a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof which are used as an IAP inhibitor, and an immune checkpoint inhibitor; and use of the combination in the preparation of a cancer treatment drug.

Abstract: This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b?/? TICs). The Cbl-b?/? TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.